Clinical Pharmacology of Drug Exposure During Repeated Assisted-Reproduction Treatment Cycles

Abstract

This review comprehensively examines the clinical pharmacology of drug exposure in patients undergoing repeated assisted-reproduction treatment (ART) cycles. With the increasing prevalence of infertility and the growing utilization of ART worldwide, understanding the pharmacokinetics, pharmacodynamics, and cumulative effects of repeated pharmacologic interventions is crucial for optimizing outcomes and minimizing adverse effects. The article synthesizes recent evidence on the safety, efficacy, and mechanistic considerations of repeated ovarian stimulation, addresses risk factors and clinical implications, and highlights practice guidelines and emerging research in this evolving field.

Introduction

The advent of assisted-reproduction technologies has revolutionized infertility management, enabling millions of couples to achieve pregnancy. Despite advances, many patients require multiple ART cycles to achieve a successful outcome, resulting in repeated exposure to a range of pharmacological agents. This pattern raises important questions about the cumulative pharmacological burden, potential risks, and optimal management strategies. A thorough understanding of the clinical pharmacology underpinning repeated ART cycles is essential for evidence-based clinical practice and patient safety.

Epidemiology / Disease Burden

Infertility affects approximately 8-12% of couples worldwide, with the demand for ART rising steadily. Data suggest that up to 50% of women undergoing ART will require more than one cycle, and a significant proportion may undergo three or more cycles before achieving a live birth. The cumulative live birth rate increases with successive cycles, but so does patient exposure to pharmacological agents such as gonadotropins, GnRH analogues, and adjunct medications, underscoring the need to balance efficacy with safety in repeated treatments.

Pathophysiology

ART protocols typically involve controlled ovarian hyperstimulation (COH) to induce multifollicular development, achieved through exogenous gonadotropins and suppression of premature luteinizing hormone surges using GnRH agonists or antagonists. Repeated stimulation cycles may alter ovarian responsiveness due to receptor downregulation, changes in intra-ovarian signaling, and potential depletion of the follicular pool. Additionally, repeated exposure to adjuvant drugs (e.g., metformin, letrozole, corticosteroids) may influence systemic and reproductive physiology, with implications for both efficacy and safety.

Risk Factors

Several factors necessitate repeated ART cycles, including advanced maternal age, diminished ovarian reserve, polycystic ovary syndrome (PCOS), endometriosis, and unexplained infertility. Patient-specific factors such as body mass index, metabolic comorbidities, and prior response to stimulation affect pharmacokinetic profiles and may influence drug accumulation or altered metabolism over successive cycles. Genetic polymorphisms in gonadotropin receptors or drug-metabolizing enzymes can further modulate individual responses and risk profiles.

Clinical Features

Clinically, repeated ART cycles may be associated with variable ovarian response, ranging from poor to hyper-response, and may influence endometrial receptivity and embryo quality. Adverse drug reactions such as ovarian hyperstimulation syndrome (OHSS), thromboembolic events, and rare long-term risks such as ovarian neoplasia may be potentiated with cumulative drug exposure. Patient-reported outcomes, including psychological stress and treatment burden, are also relevant clinical features in repeated ART contexts.

Diagnosis

Assessment prior to repeated ART cycles includes baseline and dynamic ovarian reserve testing (AMH, AFC), hormonal profiling, and evaluation of metabolic and coagulation status. Monitoring throughout cycles involves serial ultrasound and estradiol measurements to tailor drug dosing and minimize risks. Pharmacogenetic testing, though not yet routine, may become valuable in predicting individual response patterns and optimizing drug selection in repeated protocols.

Treatment & Management

Drug regimens in ART include recombinant or urinary-derived FSH, LH, hCG, and GnRH analogues, with adjuncts such as dopamine agonists, metformin, and adjuvant androgens. In repeated cycles, dose adjustment based on prior response is critical to avoid hypo- or hyperstimulation. Step-up or step-down protocols, mild stimulation regimens, and the use of GnRH antagonist-based cycles are strategies to reduce cumulative drug exposure. Supportive measures, including luteal phase support and pre-implantation genetic testing, may further individualize treatment.

Recent Advances / Emerging Therapies

Recent advances include the use of long-acting FSH formulations, individualized controlled ovarian stimulation protocols based on genetic and biochemical markers, and the integration of novel adjuvants to enhance ovarian response in poor responders. Emerging research is evaluating the impact of cumulative gonadotropin exposure on ovarian and systemic health, as well as the potential of in vitro maturation and non-hormonal ART adjuncts to minimize pharmacological burden. Artificial intelligence and machine learning are increasingly applied to predict optimal dosing and cycle management in complex cases.

Guideline Recommendations

International guidelines from ESHRE, ASRM, and WHO emphasize individualized treatment strategies, risk minimization (particularly OHSS), and cumulative live birth as the primary outcome measure. Repeated ART cycles should be planned with careful consideration of patient characteristics, prior response, and evolving evidence on drug safety. The use of mild stimulation and antagonist protocols is recommended for patients at risk of hyper-response, while regular auditing of cumulative drug doses and adverse outcomes is encouraged for quality assurance.

Conclusion

Repeated drug exposure in assisted-reproduction cycles presents complex clinical pharmacology challenges that require nuanced, evidence-based management. By integrating recent advances in pharmacogenomics, individualized protocols, and emerging therapeutics, clinicians can optimize reproductive outcomes while minimizing risks. Ongoing research and guideline updates will further refine the safe and effective use of pharmacological agents in repeated ART cycles, ultimately improving patient care in reproductive medicine.